ArticlePloS one2012
Pentraxin 3 (PTX3) expression in allergic asthmatic airways: role in airway smooth muscle migration and chemokine production.
Article in PloS one, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 42 citations in OpenAlex.
- Investigating the Therapeutic Potential of Agarwood Nanoemulsion in Modulating TGF-β-Induced Airway Remodelling in BEAS-2B Cells.Cell biochemistry and biophysics · 2026Article
- Pentraxin 3 deficiency exacerbates neutrophilic inflammation and airway hyperresponsiveness in type 2-low asthma.Frontiers in allergy · 2026Article
- Novel Serum Biomarkers for Patients with Allergic Asthma Phenotype.Biomedicines · 2024Article
- Pentraxin 3 Facilitates Shrimp-Allergic Responses in IgE-Activated Mast Cells.Journal of immunology research · 2022Article
- Endogenous Long Pentraxin 3 Exerts a Protective Role in a Murine Model of Pulmonary Fibrosis.Frontiers in immunology · 2021Article
- New Insights on the Role of pentraxin-3 in Allergic Asthma.Frontiers in allergy · 2021Review
- Perspectives on long pentraxin 3 and rheumatoid arthritis: several potential breakthrough points relying on study foundation of the past.International journal of medical sciences · 2021Review
- Pentraxin 3 promotes airway inflammation in experimental asthma.Respiratory research · 2020Article
- Soluble pattern recognition molecules: Guardians and regulators of homeostasis at airway mucosal surfaces.European journal of immunology · 2020Review
- FGF2, an Immunomodulatory Factor in Asthma and Chronic Obstructive Pulmonary Disease (COPD).Frontiers in cell and developmental biology · 2020Review
- PTX3 Intercepts Vascular Inflammation in Systemic Immune-Mediated Diseases.Frontiers in immunology · 2019Article
- Article
- Eosinophils from Physiology to Disease: A Comprehensive Review.BioMed research international · 2018Review
- Impaired response of the bronchial epithelium to inflammation characterizes severe equine asthma.BMC genomics · 2017Article
- Pentraxin 3 deletion aggravates allergic inflammation through a TThe Journal of allergy and clinical immunology · 2017Article
- Protein phosphatase 5 mediates corticosteroid insensitivity in airway smooth muscle in patients with severe asthma.Allergy · 2017Article
- Sputum pentraxin 3 as a candidate to assess airway inflammation and remodeling in childhood asthma.Medicine · 2016Article
- Macrophages redirect phagocytosis by non-professional phagocytes and influence inflammation.Nature · 2016Article
- Dysregulated function of normal human epidermal keratinocytes in the absence of filaggrin.Molecular medicine reports · 2016Article
- Functional Effects of WNT1-Inducible Signaling Pathway Protein-1 on Bronchial Smooth Muscle Cell Migration and Proliferation in OVA-Induced Airway Remodeling.Inflammation · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 2 countries.
Funding
Abstract
backgroundPentraxin 3 (PTX3) is a soluble pattern recognition receptor with non-redundant functions in inflammation and innate immunity. PTX3 is produced by immune and structural cells. However, very little is known about the expression of PTX3 and its role in allergic asthma. OBJECTIVES AND
methodsWe sought to determine the PTX3 expression in asthmatic airways and its function in human airway smooth muscle cells (HASMC). In vivo PTX3 expression in bronchial biopsies of mild, moderate and severe asthmatics was analyzed by immunohistochemistry. PTX3 mRNA and protein were measured by real-time RT-PCR and ELISA, respectively. Proliferation and migration were examined using (3)H-thymidine incorporation, cell count and Boyden chamber assays.
resultsPTX3 immunoreactivity was increased in bronchial tissues of allergic asthmatics compared to healthy controls, and mainly localized in the smooth muscle bundle. PTX3 protein was expressed constitutively by HASMC and was significantly up-regulated by TNF, and IL-1β but not by Th2 (IL-4, IL-9, IL-13), Th1 (IFN-γ), or Th-17 (IL-17) cytokines. In vitro, HASMC released significantly higher levels of PTX3 at the baseline and upon TNF stimulation compared to airway epithelial cells (EC). Moreover, PTX3 induced CCL11/eotaxin-1 release whilst inhibited the fibroblast growth factor-2 (FGF-2)-driven HASMC chemotactic activity.
conclusionsOur data provide the first evidence that PTX3 expression is increased in asthmatic airways. HASMC can both produce and respond to PTX3. PTX3 is a potent inhibitor of HASMC migration induced by FGF-2 and can upregulate CCL11/eotaxin-1 release. These results raise the possibility that PTX3 may play a dual role in allergic asthma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.